• Cardiovascular risk in PsA greater for new users of IL-12/23, IL-17 vs. TNF inhibitors

    9 days ago - By Healio

    Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data.
    “Biological disease-modifying antirheumatic drugs such as TNF, IL12/23 and IL17 inhibitors or targeted synthetic DMARDs are recommended second-line therapies for moderate to severe PsA when standard treatments (including conventional synthetic DMARDs ) fail to control disease or are not tolerated,” Laura Pina Vegas, a PhD
    Read more ...